{"doi":"10.1111/bjh.13652","title":"Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial","abstract":null,"journal":"British Journal of Haematology","year":2015,"id":16610,"datarank":2.1544541184813264,"base_score":3.6375861597263857,"endowment":3.6375861597263857,"self_citation_contribution":0.5456379239589579,"citation_network_contribution":1.6088161945223687,"self_endowment_contribution":0.5456379239589579,"citer_contribution":1.6088161945223687,"corpus_percentile":null,"corpus_rank":null,"citation_count":37,"citer_count":34,"citers_with_citation_signal":28,"citers_with_endowment":28,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":121944,"name":"Axel Benner","orcid":null,"position":1,"is_corresponding":false},{"id":121945,"name":"Fabienne McClanahan","orcid":null,"position":2,"is_corresponding":false},{"id":121946,"name":"Jennifer Klemmer","orcid":null,"position":3,"is_corresponding":false},{"id":121947,"name":"Julia Brandt","orcid":null,"position":4,"is_corresponding":false},{"id":121948,"name":"Elke Brants","orcid":null,"position":5,"is_corresponding":false},{"id":121949,"name":"Michael Rieger","orcid":null,"position":6,"is_corresponding":false},{"id":121950,"name":"Julia Meissner","orcid":null,"position":7,"is_corresponding":false},{"id":121951,"name":"Manfred Hensel","orcid":null,"position":8,"is_corresponding":false},{"id":121952,"name":"Kai Neben","orcid":null,"position":9,"is_corresponding":false},{"id":121953,"name":"Peter Dreger","orcid":null,"position":10,"is_corresponding":false},{"id":121954,"name":"Eva Lengfelder","orcid":null,"position":11,"is_corresponding":false},{"id":121955,"name":"Ingo Schmidt-Wolf","orcid":null,"position":12,"is_corresponding":false},{"id":121956,"name":"Alwin Krämer","orcid":null,"position":13,"is_corresponding":false},{"id":121957,"name":"Anthony D. Ho","orcid":null,"position":14,"is_corresponding":false},{"id":121943,"name":"Mathias Witzens-Harig","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":3.6375861597263857,"endowment":3.6375861597263857,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26449739","pmcid":null,"openalex_id":"https://openalex.org/W1946250925","authors":[],"funders":[{"funder_name":"Roche","grant_id":"","title":null}],"total_grants":1,"fwci":3.7622,"citation_percentile":0.93051007,"influential_citations":0,"citation_trend":[{"year":2016,"count":1},{"year":2017,"count":11},{"year":2018,"count":5},{"year":2019,"count":3},{"year":2020,"count":3},{"year":2021,"count":4},{"year":2022,"count":3},{"year":2023,"count":3},{"year":2024,"count":1},{"year":2025,"count":1},{"year":2026,"count":2}],"oa_status":"bronze","license":"http://doi.wiley.com/10.1002/tdm_license_1","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.13652","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.13652","host_type":"BRONZE"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/bjh.13652","host_type":"publisher"},{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fbjh.13652","host_type":"publisher"},{"url":"http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13652/fullpdf","host_type":"publisher"},{"url":"https://doi.org/10.1111/bjh.13652","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/26449739","host_type":"repository"}],"fields_of_study":["Lymphoma Diagnosis and Treatment","Viral-associated cancers and disorders","CAR-T cell therapy research","Medicine","Adult","Aged","Aged, 80 and over","Antineoplastic Agents","Drug Administration Schedule","Female","Humans","Lymphoma, Large B-Cell, Diffuse","Male","Middle Aged","Prospective Studies","Rituximab","Treatment Outcome"],"mesh_terms":["Rituximab","Adult","Aged","Aged, 80 and over","Antineoplastic Agents","Drug Administration Schedule","Female","Humans","Male","Middle Aged","Prospective Studies","Lymphoma, Large B-Cell, Diffuse","Treatment Outcome"],"keywords":["Hazard ratio","Medicine","Rituximab","Internal medicine","Log-rank test","Proportional hazards model","Diffuse large B-cell lymphoma","Randomized controlled trial","Subgroup analysis","Confidence interval","Lymphoma","Survival analysis","Prospective cohort study","Progression-free survival","Oncology","Gastroenterology","Chemotherapy","Surgery","Gender Differences","Multicentre Prospective Randomized Trial","Rituximab Maintenance Therapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-02T11:59:30.785163Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}